• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:王开运,彭晓星,任德全,何岳义,黄华,韩鹏飞,邓杜萍,苏龙.持续硬膜外神经阻滞联合舒风解毒汤治疗带状疱疹神经痛的临床疗效探讨[J].药学研究,2026,45(9):1065-1071[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 245次   下载 201次 本文二维码信息
码上扫一扫!
持续硬膜外神经阻滞联合舒风解毒汤治疗带状疱疹神经痛的临床疗效探讨
王开运1,彭晓星1,任德全1,何岳义1,黄华1,韩鹏飞1,邓杜萍1,苏龙2
字体:加大+|默认|缩小-
(1.眉山市中医医院,四川 眉山 620010;2.仁寿县第三人民医院,四川 眉山 620599)
摘要:
目的 探究持续硬膜外神经阻滞(CEA)联合舒风解毒汤治疗带状疱疹(HZ)神经痛患者的临床疗效。方法 前瞻性选取186例HZ神经痛患者,按随机数字表分为A组(CEA+舒风解毒汤)、B组(CEA)、C组(舒风解毒汤)各62例,疗程4周,随访3个月。比较3组的疗效、免疫功能、疼痛介质与炎症因子[神经肽P物质(SP)、β-内啡肽(β-EP)、神经激肽(NK)-1、干扰素(IFN)-γ、白细胞介素-10(IL-10)、IL-2]、疼痛相关指标、安全性及后遗神经痛发生率。结果 治疗4周后,A组疗效高于B、C组(P<0.05);A组CD3+、CD4+、CD4+/CD8+、β-EP、IFN-γ、IL-2水平高于B、C组,CD8+、SP、NK-1、IL-10水平低于B、C组(P<0.05);A组各时间点视觉模拟评分、24 h爆发痛次数、补救镇痛率及睡眠质量评分低于B、C组,镇痛满意度高于B、C组(P<0.05);3组不良反应无显著差异(P>0.05);随访3月,A组后遗神经痛发生率低于B、C组(P<0.05)。结论 CEA联合舒风解毒汤治疗可有效改善HZ神经痛患者的免疫状态,调控疼痛与炎症因子,减轻疼痛,降低后遗神经痛风险,且安全性好。
关键词:  带状疱疹神经痛  持续硬膜外神经阻滞  舒风解毒汤  疗效  疼痛介质
DOI:10.13506/j.cnki.jpr.2026.09.016
基金项目:眉山市科技指导性计划项目(No.2024KJZD095)
收稿日期:2026-03-18   修回日期:2026-04-22   出版日期:2026-09-30
Clinical curative effect of continuous epidural analgesia combined with Shufeng Jiedu Decoction in herpes zoster neuralgia
WANG Kaiyun1,PENG Xiaoxing1,REN Dequan1,HE Yueyi1,HUANG Hua1,HAN Pengfei1,DENG Duping1,SU Long2
(1.Meishan Hospital of Traditional Chinese Medicine,Meishan 620000,China;2.The Third People's Hospital of Renshou County,Meishan 620000,China)
Abstract:
Objective To explore clinical curative effect of continuous epidural analgesia (CEA) combined with Shufeng Jiedu Decoction in patients with herpes zoster (HZ) neuralgia.Methods According to random number table method, 186 patients with HZ neuralgia were prospectively enrolled and divided into group A (CEA+Shufeng Jiedu Decoction), group B (CEA) and group C (Shufeng Jiedu Decoction, n=62), 62 cases/group. All were treated for 4 weeks and followed up for 3 months. Curative effect, immune function, pain mediators and inflammatory factors [Neuropeptide substance P (SP), β-endorphin (β-EP), neurokinin (NK)-1, interferon (IFN) -γ, interleukin-10(IL-10), IL-2], pain-related indexes, safety and incidence of postherpetic neuralgia were compared among the three groups.Results After 4 weeks of treatment, curative effect of group A was better than that of groups B and C (P<0.05). Compared with groups B and C, levels of CD3+, CD4+, CD4+/CD8+, β-EP, IFN-γ and IL-2 were higher, while levels of CD8+, SP, NK-1 and IL-10 were lower in group A (P<0.05). Compared with groups B and C, scores of visual analogue scale (VAS) at different time points, frequency of 24 h breakthrough pain, remedial analgesia rate and score of sleep quality were lower, while analgesia satisfaction was higher in group A (P<0.05). There was no significant difference in adverse reactions among the three groups (P>0.05). After 3 months of follow-up, incidence of postherpetic neuralgia in group A was lower than that in groups B and C (P<0.05). Conclusion CEA combined with Shufeng Jiedu Decoction can effectively improve immune status, regulate pain and inflammatory factors, relieve pain and reduce the risk of postherpetic neuralgia in patients with HZ neuralgia, which has good safety.
Key words:  Herpes zoster neuralgia  Continuous epidural analgesia  Shufeng Jiedu Decoction  Curative effect  Pain mediator
今日访问量:2433    总访问量:55338849
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司